China (Mainland)
Diamondsupplier 
factory supply GMP,DMF Lopinavir CAS NO.155213-67-5
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T,Other
- Product Details
Keywords
- Lopinavir
- Anti-AIDS
- 155213-67-5
Quick Details
- ProName: factory supply GMP,DMF Lopinavir
- CasNo: 155213-67-5
- Molecular Formula: C37H48N6O5S2
- Appearance: White crystallization
- Application: Anti- Virus response
- DeliveryTime: in two weeks
- PackAge: 1kg/tin
- Port: SHANGHAI BEIJING
- ProductionCapacity: 1 Metric Ton/Day
- Purity: USP/EP/BP
- Transportation: AIR SEA TRAIN
- LimitNum: 1 Kilogram
Superiority
We are very compeitive on Lopinavir.Our mfr is GMP certified for this item with DMF document.
| Product Name: | Lopinavir |
| Synonyms: | LOPINAVIR;(2s)-n-[(2r,4s,5s)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenyl-hexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide;(aS)-N-[(1S,3S,4S)-4-[[2-(2,6-Dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-a-(1-methylethyl)-2-oxo-1(2H)-Pyrimidineacetamide;A 157378.0;ABT 378;Aluviran;Koletr;134368 |
| CAS: | 192725-17-0 |
| MF: | C37H48N4O5 |
| MW: | 628.81 |
| EINECS: | 200-001-8 |
| Product Categories: | Pharmaceutical;Other APIs;Anti-viral Compounds;Anti-virals;Intermediates & Fine Chemicals;Chiral Reagents;Non-nucleoside Reverse Transcriptase;Pharmaceuticals;Pepetides;ProteaseInhibitors;API;peptides;ABT-378 |
| Mol File: | 192725-17-0.mol |
Details
| Lopinavir Chemical Properties |
| Melting point | 255.2-260.6 °F (124—127°C) |
| Boiling point | 924.1±65.0 °C(Predicted) |
| density | 1.163±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: soluble20mg/mL, clear |
| form | powder |
| pka | 13.89±0.46(Predicted) |
| color | white to beige |
| optical activity | [α]/D -20 to -27°, c = 0.4 in methanol |
| Stability: | Hygroscopic |
| CAS DataBase Reference | 192725-17-0(CAS DataBase Reference) |
| Safety Information |
| RIDADR | 3077 |
| HS Code | 29335990 |
| Hazardous Substances Data | 192725-17-0(Hazardous Substances Data) |
| MSDS Information |
| Lopinavir Usage And Synthesis |
| Description | Lopinavir, the sixth HIV protease inhibitor in the “navir” class, was launched in coformulation with ritonavir, another HIV protease inhibitor already marketed (Abbott, 1996); this original formulation was introduced as Kaletra for use in combination with either nucleoside or non-nucleoside reverse transcriptase inhibitors for the treatment of AIDS in adults and children. Lopinavir is a peptidomimetic compound with a structural core identical to that of ritonavir, on which terminal groups, particularly a modified valine, were introduced by peptide coupling procedures. Lopinavir is a potent competitive inhibitor of HIV-I protease exhibiting high potential against ritonavir-resistant mutations. In several animal species, pharmacokinetic studies with the lopinavirlritonavir association showed that the modest properties of lopinavir were significantly improved in presence of ritonavir, in terms of Cmax and duration of action. Ritonavir inhibits the P450 isoenzyme CYP3A4 and the human liver microsomal metabolism of lopinavir, so strongly amplifying plasma levels of this latter component. In AIDS patients, the plasma HIV RNA level was considerably reduced and the CD4+ T-cell counts increased after administration of lopinavir combined with relatively small doses of ritonavir. Kaletra is intended to be used jointly with other antiretroviral agents. |
| Chemical Properties | White Crystalline Solid |